Bendectin and birth defects: the challenges of mass toxic substances litigation
Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Philadelphia
Univ. of Pennsylvania Press
1996
|
| Schlagworte: | |
| Zusammenfassung: | Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation. |
| Beschreibung: | XIII, 368 S. |
| ISBN: | 0812232577 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV011180066 | ||
| 003 | DE-604 | ||
| 005 | 19970211 | ||
| 007 | t | ||
| 008 | 970203s1996 |||| 00||| engod | ||
| 020 | |a 0812232577 |9 0-8122-3257-7 | ||
| 035 | |a (OCoLC)33334546 | ||
| 035 | |a (DE-599)BVBBV011180066 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a KF1297.D7 | |
| 082 | 0 | |a 347.30638 |2 20 | |
| 082 | 0 | |a 346.7303/8 |2 20 | |
| 100 | 1 | |a Green, Michael D. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Bendectin and birth defects |b the challenges of mass toxic substances litigation |c Michael D. Green |
| 264 | 1 | |a Philadelphia |b Univ. of Pennsylvania Press |c 1996 | |
| 300 | |a XIII, 368 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 520 | 3 | |a Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation. | |
| 650 | 4 | |a Abnormalities, Drug-Induced |z United States |v Legislation | |
| 650 | 4 | |a Abnormalities, Human | |
| 650 | 4 | |a Bendectin (Trademark) |x Toxicology | |
| 650 | 4 | |a Complex litigation |z United States | |
| 650 | 4 | |a Consumer Product Safety |z United States |v Legislation | |
| 650 | 4 | |a Doxylamine |x adverse effects |z United States |v Legislation | |
| 650 | 4 | |a Products liability |x Drugs |z United States | |
| 650 | 4 | |a Pyridoxine |x adverse effects |z United States |v Legislation | |
| 650 | 4 | |a Toxic torts |z United States | |
| 650 | 0 | 7 | |a Geschichte |0 (DE-588)4020517-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Produzentenhaftung |0 (DE-588)4047375-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Teratogenität |0 (DE-588)4583871-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kombinationspräparat |0 (DE-588)4197323-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Doxylaminsuccinat |0 (DE-588)4306104-7 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 655 | 7 | |0 (DE-588)4522595-3 |a Fallstudiensammlung |2 gnd-content | |
| 655 | 7 | |a Dicycloverin |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |D s |
| 689 | 0 | 2 | |a Produzentenhaftung |0 (DE-588)4047375-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Dicycloverin |A f |
| 689 | 1 | 1 | |a Doxylaminsuccinat |0 (DE-588)4306104-7 |D s |
| 689 | 1 | 2 | |a Kombinationspräparat |0 (DE-588)4197323-9 |D s |
| 689 | 1 | 3 | |a Teratogenität |0 (DE-588)4583871-9 |D s |
| 689 | 1 | 4 | |a Produzentenhaftung |0 (DE-588)4047375-2 |D s |
| 689 | 1 | 5 | |a Geschichte |0 (DE-588)4020517-4 |D s |
| 689 | 1 | |5 DE-604 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007497198 | ||
Datensatz im Suchindex
| _version_ | 1804125675361140736 |
|---|---|
| any_adam_object | |
| author | Green, Michael D. |
| author_facet | Green, Michael D. |
| author_role | aut |
| author_sort | Green, Michael D. |
| author_variant | m d g md mdg |
| building | Verbundindex |
| bvnumber | BV011180066 |
| callnumber-first | K - Law |
| callnumber-label | KF1297 |
| callnumber-raw | KF1297.D7 |
| callnumber-search | KF1297.D7 |
| callnumber-sort | KF 41297 D7 |
| callnumber-subject | KF - United States |
| ctrlnum | (OCoLC)33334546 (DE-599)BVBBV011180066 |
| dewey-full | 347.30638 346.7303/8 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 347 - Procedure and courts 346 - Private law |
| dewey-raw | 347.30638 346.7303/8 |
| dewey-search | 347.30638 346.7303/8 |
| dewey-sort | 3347.30638 |
| dewey-tens | 340 - Law |
| discipline | Rechtswissenschaft |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03087nam a2200661 c 4500</leader><controlfield tag="001">BV011180066</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19970211 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">970203s1996 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0812232577</subfield><subfield code="9">0-8122-3257-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)33334546</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011180066</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">KF1297.D7</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">347.30638</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">346.7303/8</subfield><subfield code="2">20</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Green, Michael D.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bendectin and birth defects</subfield><subfield code="b">the challenges of mass toxic substances litigation</subfield><subfield code="c">Michael D. Green</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia</subfield><subfield code="b">Univ. of Pennsylvania Press</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 368 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abnormalities, Drug-Induced</subfield><subfield code="z">United States</subfield><subfield code="v">Legislation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abnormalities, Human</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bendectin (Trademark)</subfield><subfield code="x">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Complex litigation</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Consumer Product Safety</subfield><subfield code="z">United States</subfield><subfield code="v">Legislation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxylamine</subfield><subfield code="x">adverse effects</subfield><subfield code="z">United States</subfield><subfield code="v">Legislation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Products liability</subfield><subfield code="x">Drugs</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pyridoxine</subfield><subfield code="x">adverse effects</subfield><subfield code="z">United States</subfield><subfield code="v">Legislation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxic torts</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Teratogenität</subfield><subfield code="0">(DE-588)4583871-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kombinationspräparat</subfield><subfield code="0">(DE-588)4197323-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Doxylaminsuccinat</subfield><subfield code="0">(DE-588)4306104-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4522595-3</subfield><subfield code="a">Fallstudiensammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Dicycloverin</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Dicycloverin</subfield><subfield code="A">f</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Doxylaminsuccinat</subfield><subfield code="0">(DE-588)4306104-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Kombinationspräparat</subfield><subfield code="0">(DE-588)4197323-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Teratogenität</subfield><subfield code="0">(DE-588)4583871-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="4"><subfield code="a">Produzentenhaftung</subfield><subfield code="0">(DE-588)4047375-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="5"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007497198</subfield></datafield></record></collection> |
| genre | (DE-588)4522595-3 Fallstudiensammlung gnd-content Dicycloverin gnd |
| genre_facet | Fallstudiensammlung Dicycloverin |
| geographic | USA USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV011180066 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T18:05:20Z |
| institution | BVB |
| isbn | 0812232577 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007497198 |
| oclc_num | 33334546 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XIII, 368 S. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Univ. of Pennsylvania Press |
| record_format | marc |
| spelling | Green, Michael D. Verfasser aut Bendectin and birth defects the challenges of mass toxic substances litigation Michael D. Green Philadelphia Univ. of Pennsylvania Press 1996 XIII, 368 S. txt rdacontent n rdamedia nc rdacarrier Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation. Abnormalities, Drug-Induced United States Legislation Abnormalities, Human Bendectin (Trademark) Toxicology Complex litigation United States Consumer Product Safety United States Legislation Doxylamine adverse effects United States Legislation Products liability Drugs United States Pyridoxine adverse effects United States Legislation Toxic torts United States Geschichte (DE-588)4020517-4 gnd rswk-swf Produzentenhaftung (DE-588)4047375-2 gnd rswk-swf Teratogenität (DE-588)4583871-9 gnd rswk-swf Arzneimittelsicherheit (DE-588)4143182-0 gnd rswk-swf Kombinationspräparat (DE-588)4197323-9 gnd rswk-swf Doxylaminsuccinat (DE-588)4306104-7 gnd rswk-swf USA USA (DE-588)4078704-7 gnd rswk-swf (DE-588)4522595-3 Fallstudiensammlung gnd-content Dicycloverin gnd rswk-swf USA (DE-588)4078704-7 g Arzneimittelsicherheit (DE-588)4143182-0 s Produzentenhaftung (DE-588)4047375-2 s DE-604 Dicycloverin f Doxylaminsuccinat (DE-588)4306104-7 s Kombinationspräparat (DE-588)4197323-9 s Teratogenität (DE-588)4583871-9 s Geschichte (DE-588)4020517-4 s |
| spellingShingle | Green, Michael D. Bendectin and birth defects the challenges of mass toxic substances litigation Abnormalities, Drug-Induced United States Legislation Abnormalities, Human Bendectin (Trademark) Toxicology Complex litigation United States Consumer Product Safety United States Legislation Doxylamine adverse effects United States Legislation Products liability Drugs United States Pyridoxine adverse effects United States Legislation Toxic torts United States Geschichte (DE-588)4020517-4 gnd Produzentenhaftung (DE-588)4047375-2 gnd Teratogenität (DE-588)4583871-9 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd Kombinationspräparat (DE-588)4197323-9 gnd Doxylaminsuccinat (DE-588)4306104-7 gnd |
| subject_GND | (DE-588)4020517-4 (DE-588)4047375-2 (DE-588)4583871-9 (DE-588)4143182-0 (DE-588)4197323-9 (DE-588)4306104-7 (DE-588)4078704-7 (DE-588)4522595-3 |
| title | Bendectin and birth defects the challenges of mass toxic substances litigation |
| title_auth | Bendectin and birth defects the challenges of mass toxic substances litigation |
| title_exact_search | Bendectin and birth defects the challenges of mass toxic substances litigation |
| title_full | Bendectin and birth defects the challenges of mass toxic substances litigation Michael D. Green |
| title_fullStr | Bendectin and birth defects the challenges of mass toxic substances litigation Michael D. Green |
| title_full_unstemmed | Bendectin and birth defects the challenges of mass toxic substances litigation Michael D. Green |
| title_short | Bendectin and birth defects |
| title_sort | bendectin and birth defects the challenges of mass toxic substances litigation |
| title_sub | the challenges of mass toxic substances litigation |
| topic | Abnormalities, Drug-Induced United States Legislation Abnormalities, Human Bendectin (Trademark) Toxicology Complex litigation United States Consumer Product Safety United States Legislation Doxylamine adverse effects United States Legislation Products liability Drugs United States Pyridoxine adverse effects United States Legislation Toxic torts United States Geschichte (DE-588)4020517-4 gnd Produzentenhaftung (DE-588)4047375-2 gnd Teratogenität (DE-588)4583871-9 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd Kombinationspräparat (DE-588)4197323-9 gnd Doxylaminsuccinat (DE-588)4306104-7 gnd |
| topic_facet | Abnormalities, Drug-Induced United States Legislation Abnormalities, Human Bendectin (Trademark) Toxicology Complex litigation United States Consumer Product Safety United States Legislation Doxylamine adverse effects United States Legislation Products liability Drugs United States Pyridoxine adverse effects United States Legislation Toxic torts United States Geschichte Produzentenhaftung Teratogenität Arzneimittelsicherheit Kombinationspräparat Doxylaminsuccinat USA Fallstudiensammlung Dicycloverin |
| work_keys_str_mv | AT greenmichaeld bendectinandbirthdefectsthechallengesofmasstoxicsubstanceslitigation |